Yahoo
NasdaqGM - Nasdaq Real Time Price USD

TransMedics Group, Inc. (TMDX)

88.24 +19.26 (+27.92%)
At close: November 6 at 4:00:01 PM EST
88.10 -0.14 (-0.16%)
After hours: November 6 at 6:58:24 PM EST
Trade TMDX on Coinbase
TMDX Q3 2026 earnings call
Replay the call for the latest insights.
Read transcript

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Dr. Waleed H. Hassanein M.D.
Founder, President, CEO & Director 2.19M -- 1968
Mr. Nicholas Corcoran
Senior Vice President of Supply Chain & Operations 865.84k -- 1982
Dr. Tamer I. Khayal M.D.
Senior Vice President of International 1.04M 70.82k 1969
Mr. Fernando Araujo
Chief Financial Officer & Treasurer -- -- 1980
Mr. Matthew Forsyth
Senior VP, General Counsel & Corporate Secretary -- -- --
Ms. Miriam C. Provost Ph.D.
Vice President of Global Regulatory Affairs 535.93k 390.25k 1961

TransMedics Group, Inc.

200 Minuteman Road
Suite 302
Andover, MA 01810
United States
978 552 0900 https://www.transmedics.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
898

Description

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Corporate Governance

TransMedics Group, Inc.’s ISS Governance QualityScore as of November 1, 2026 is 5. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 3; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 5, 2026 at 9:00 PM UTC

TransMedics Group, Inc. Earnings Date

Recent Events

November 5, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 10, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 4, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 29, 2026 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

May 21, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 7, 2026 at 12:00 AM UTC

DEFA14A: Proxy Statements

May 5, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 10, 2026 at 12:00 AM UTC

DEF 14A: Proxy Statements

February 27, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 24, 2026 at 12:00 AM UTC

10-K: Periodic Financial Reports

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: